Orphan Drug Designation Granted to Nintedanib
Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Today, Boehringer Ingelheim sent out a press release, announcing that, “… the European Commission (EC) and U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD)”.
Joep Welling from Fesca says: “Scleroderma and associated interstitial lung disease have a devastating impact on the patient community, and we welcome this important news that a potential new treatment has received Orphan Drug Designation. It’s a crucial step forward in helping to address an unmet need and represents important progress for patients with this rare disease.”
news & events
Article by doctor Susana Oliveira, graduated Hospital Assistant and Systemic Sclerosis Consulting Coordinator at the Professor Doutor Fernando Fonseca Hospital
Artikel von Maria José Guimarães, Pulmonologin, Koordinatorin des pneumologischen Dienstes des Krankenhauses von Luz-Guimarães.
Opinion article by Dr. Maria José Guimarães, Pulmonologist, Coordinator of the Pneumology Service of the Luz-Guimarães Hospital